A Pilot Text Messaging Intervention to Reduce Smoking in Office-based Buprenorphine and Inpatient Detoxification Patients

Mobile Phone Messaging to Support Smoking Cessation Among Office-based Buprenorphine and Inpatient Detoxification Patients: a Pilot Study

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02665208

Enrollment

203

Registered

2016-01-27

Start date

2015-03-31

Completion date

2017-09-30

Last updated

2017-12-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Smoking Cessation

Keywords

cigarettes, smoking, opiate-dependence, alcohol, detoxification

Brief summary

The primary purpose of this study is to understand the feasibility of a text messaging intervention developed by the National Cancer Institute, known as Smokefreetxt, to improve smoking cessation among opiate and/or alcohol dependent participants discharged from an inpatient detoxification unit and enrolled in an office-based buprenorphine program patients (OBBP). Participants will be randomized to 1) treatment as usual (TAU) comprised of informational pamphlets and information for a 1800 quit line; and a prescription for a nicotine replacement therapy (NRT) (i.e. nicotine replacement patches based on the quantity of baseline self-reported smoking, or nicotine replacement gum (2mg) #10, for 28 days which is offered routinely to all inpatients at Bellevue at the time of discharge) versus the SmokeFreeTXT intervention plus prescriptions for NRT.

Interventions

OTHERTreatment As Usual (TAU)

informational pamphlets and information from 1800 quit line + prescription for nicotine replacement therapy (NRT) based on on the quantity of baseline self-reported smoking, or nicotine replacement gum (2mg)

DRUGNicotine Replacement Therapies

a prescription for a nicotine replacement therapy (NRT) (i.e. nicotine replacement patches based on the quantity of baseline self-reported smoking, or nicotine replacement gum (2mg)

BEHAVIORALText Message Intervention (TMI)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

SUPPORTIVE_CARE

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* self-described every or some day smoker * diagnosed with opiate dependence and/or alcohol dependence (DSM-IV) per Physician medical records (MISYS) * Fluency in English and able to provide a written informed consent * Currently owning a mobile phone with a working phone number * Expected to reside in the New York City area for the next 12 months * Understands and able to respond to the intervention text message

Exclusion criteria

* inability to read or understand English * currently using nicotine replacement therapies (patch, gum, e-cigarettes), pharmacotherapy for smoking cessation such as bupropion (zyban, wellbutrin), varenicline (Chantix). * suicidal or homicidal ideations * any ongoing psychotic disorder, life-threatening medical or psychiatric condition * leaves the inpatient detoxification unit prior to completing study enrollment * is pregnant, nursing or planning to conceive within the duration of the study period

Design outcomes

Primary

Measure	Time frame
Difference in patient acceptability assessed via rates of participant adoption of TMI	24 Weeks
Feasibility measured by rates of retention in the TMI	24 Weeks
Clinical impact assessed using self-reported abstinence at week 1 via a text message inquiry from study	24 Weeks

Secondary

Measure	Time frame
Change in pattern of mobile device, computer, and internet usage.	24 Weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026